PNIBLOG

Glioblastoma MDNA55 Trial Medicenna

Pacific Neuroscience Institute, the leading enrollment site for the MDNA55 clinical trial for Glioblastoma, is still open and enrolling eligible patients. This innovative phase 2 study is for the minimally invasive convection-enhanced delivery (CED) of a new bioengineered targeted therapeutic, MDNA55, in adults with recurrent or progressive glioblastoma. Read more.

Clinical Trials at Pacific Neuroscience Institute

Pacific Neuroscience Institute opens up two new clinical trials this month, one in Essential Tremor and one in Glioblastoma. Find out more about these new trials as well as the other available open neurological studies.

Pacific Neuroscience Institute Clinical Trials

Find out about the latest clinical trials at Pacific Neuroscience Institute for brain tumor, stroke, movement disorders, and other neurological areas. Call our center at 310-829-8265 to enroll.

Sarah McEwen PhD

Dr. Sarah McEwen’s determination to make a difference bridges the gap between academic research and the underserved populations in the community. Her research and clinical work implement physical and cognitive interventions simultaneously during the earliest phases of illness with the possibility of preventing cognitive decline. Read more.

Clinical Trials Round-Up at PNI

Find out about the latest clinical trials at Pacific Neuroscience Institute for brain tumor, stroke and other neurological areas. Call our center at 310-829-8265 to enroll.

Boston Biomedical Wizard201G Trial at Pacific Neuroscience Institute

The Wizard201G clinical trial from Boston Biomedical Inc. is a vaccine treatment for patients with recurrent or progressive GBM following initial treatment. Pacific Neuroscience Institute is a site for this phase 2 study which is currently recruiting. Contact us for eligibility criteria at 310-582-7460.